Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Irisbiosciences a New Player in 3D Cell Culture

Published: Friday, February 14, 2014
Last Updated: Friday, February 14, 2014
Bookmark and Share
Irisbiosciences is focused on the development, manufacturing and marketing of products for bio-/pharmaceutical research and development, namely 3D cell culture products, tissue models and human & stem cells for in-vitro experimentation.

Company premises include a GMP facility with clean rooms (Classes A, C and D) and the company operates 250 m2 of fully equipped BSL Level 2, R&D, Analytical and QC laboratories for development of medical devices and tissue engineering products. 

irisbiosciences provides 3D cell culture products , as well as contract research and manufacturing services in cell based essays and cell based products. 


mimsys® for 3D Cell culture 
mimsys® G is a xeno-free and non-immunogenic hydrogel, easy to handle, for cell encapsulation in 3D experiments in vitro or in vivo. mimsys® G is nutrient permeable and allows long term 3D cell culture, at least 21 days of proliferation and survival. The transparency of mimsys® G hydrogel make it suitable for established laboratorial cell assays, such as cell differentiation, microscopy evaluations, viability protocols and histological procedures. Protocol handbook is available upon request. 

Human Mesenchymal Stem Cells 
High quality and high purity mesenchymal stem cells are obtained from human adipose tissue. These cells can be applied in a broad range of basic and applied research contexts. Tissue processing, cell isolation and cryopreservation are performed under Good Manufacturing Practices (cGMP), using xeno-free and GMP reagents. Cells have very low levels of manipulation which minimizes genomic instability. Frozen vials are provided with indication of donor age, gender, ethnicity, Body Mass Index (BMI) and anatomical harvesting location. Protocol handbook is available upon request. 


Contract Research 
irisbiosciences provides contract research services on medical device and advanced therapy medicinal products, by encompassing experimental development, in vitro performance assessment and in vivo testing. Our skill set includes strong competence in biomaterials’ development and cell culturing technologies, and extensive knowledge and experience in tissue engineering and regenerative medicine. 

irisbiosciences provides: 

  • Biomaterials development and testing; 
  • Cell based assays development and validation; 
  • Cell isolation and cell manipulation protocol development; 
  • Development and testing of cell based products. 

Contract Manufacturing Services : 

irisbiosciences provides a wide range of cGMP services concerning human tissue, cells and related products, including tissue processing, manufacturing of cell-based products, as well as cell manufacturing and banking. 

The facility comprises 250 m2 of qualified controlled environment rooms (CERs), or clean rooms, and material pass-throughs. The CERs are designed to maximize environmental quality, allow the manufacturing of sterile products and are compliant with all the requirements of the European Union Tissue and Cells Directives (EUTCD) and the guidelines for cGMP.To insure the highest levels of quality and regulatory compliance, we have implemented and follow a complete Quality System in conformity with EU-GMP Guide/ICH Q7 and ISO 9001:2008. 

irisbiosciences performs a comprehensive range of analytical testing to ensure product quality and demonstrate the control of viable and non-viable particles, in all irisbiosciences CERs associated with the aseptic preparation process. Quality control tests include LAL test for bacterial endotoxin quantification; mycoplasma detection by conventional PCR, and microbial contaminants detection / Sterility tests. For detection of microbial contaminants, irisbiosciences is equipped with Bact/ALERT Microbial Detection System requirements. 

Our Facilities/Equipment description: 

  • 6 cGMP compliant cleanroom areas; 
  • 3 Grade C/ISO 7 manufacturing rooms fitted with aseptic Isolators with positive pressure; 
  • 1 Grade D/ISO 8 support room and cryostorage room; 
  • 2 HVAC systems for continuity of processing; 
  • Dedicated clean room and facility monitoring system; 
  • Dedicated manufacturing room for cell expansion; 
  • O2 and CO2 controlled incubation. 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos